<DOC>
	<DOCNO>NCT00199108</DOCNO>
	<brief_summary>Patients acute lymphoblastic leukaemia aggressive lymphoma document isolated CNS relapse CNS relapse combine relapse site receive therapy intrathecal DepoCyte least . Treatment may repeat induction phase 2 week monthly maintenance phase . The study aim replace usual 2-3 weekly application intrathecal triple therapy one application DepoCyte . Primary objective response rate one application DepoCyte . Further objectives compilation data regard safety toxicity</brief_summary>
	<brief_title>Treatment Acute Lymphoblastic Leukemia Aggressive Lymphoma With Relapse Central Nervous System With Depocyt</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<criteria>proven diagnosis ALL aggressive NonHodgkinLymphoma ( Burkitt/Burkittlike ) CNS relapse CNS involvement demonstrate positive ventricular lumbar CSF cytology characteristic sign symptom neoplastic meningitis plus MRI CT scan indicate presence meningeal involvement combine relapse CNS location : systemic therapy CNS active drug postpone least 2 week Karnofsky Performance Score &gt; = 60 % 18 year age old free uncontrolled infection recover grade III / IV toxicity attributable prior treatment exception hematotoxicity patient pregnant breast feed effective method prevent pregnancy free severe heart , lung , liver kidney dysfunction write informed consent fail respond ( defined clearance CSF ) &gt; 1 dose prior i.th . MTX ARAC triple therapy history neurotoxicity ( grade III IV ) attribute i.th . systemic HD therapy MTX ARAC prior CNS relapse &lt; 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>CNS relapse</keyword>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
</DOC>